Synonyms: Example 1 [WO2016119505A1] | Keprason®
keverprazan is an approved drug (China (2023))
Compound class:
Synthetic organic
Comment: Keverprazan (hydrochloride) is a potassium ion-competitive acid blocker (P-CAB) [3], that was developed to decrease gastric acid production. P-CABs inhibit the gastric H+,K+-ATPase, and are therapeutic alternatives to long-used proton pump inhibitors [4].
P-CABs are an evolving class of drugs, the first of which to enter clinical use was revaprazan in 2007 (S Korea). |
|
References |
1. Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y et al.. (2022)
The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther, 55 (12): 1524-1533. [PMID:35505467] |
2. Kang C. (2023)
Keverprazan Hydrochloride: First Approval. Drugs, 83 (7): 639-643. [PMID:37074491] |
3. Qin Y, Koh S, Jin Q, Chen T, Jiang J. (2016)
Pyrrole sulfonyl derivative, and preparation method and medical use thereof. Patent number: WO2016119505A1. Assignee: Jiangsu Kefeiping Medical Co., Ltd., Nanjing Kefeiping Shenghui Pharmaceutical Co., Ltd.. Priority date: 11/11/2015. Publication date: 04/08/2016. |
4. Rawla P, Sunkara T, Ofosu A, Gaduputi V. (2018)
Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?. World J Gastrointest Pharmacol Ther, 9 (7): 63-68. [PMID:30595950] |
5. Tan ND, Liu XW, Liu CX, Li SB, Chen HH, Li X, Wu H, Liao AJ, Zhen YB, Shen PZ et al.. (2022)
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol, 37 (11): 2060-2066. [PMID:36068945] |